Evidence map›Paper›PMID 28416506›Full record

ReviewBlood2017

Clinical updates in adult immune thrombocytopenia.

Michele P Lambert, Terry B Gernsheimer

5 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 180 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
180citing papers in PubMed, 10 pooled it
30.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03324087 unknown statusnot on this map

A Multi-Center Prospective Study of Evaluating Health Related Quality of Life in Adult With Immune Thrombocytopenia in China Using Real-world Data

TypeobservationalSponsorShandong UniversityRan2017 to 2018Enrolled1,000ConditionsImmune ThrombocytopeniaArmsHRQoL
NCT04482777 unknown statusnot on this mapstarted 2023, after this paper: background citation

IL37,Tlymphocytes ,NK Cells in Pathogenesis of Immune Thrombocytopenia.

TypeobservationalSponsorAssiut UniversityRan2023 to 2023Enrolled90ConditionsITPArmsCorticosteriod for treated patients
NCT06479291 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Efficacy and Safety of Hydroxychloroquine Plus TPO-RA in Antinuclear Antibody-positive Patients With Primary Immune Thrombocytopenia-- The Multicenter, Randomized, Open-labled Clinical Trial

TypeinterventionalSponsorYunfeng ChengRan2024 to 2026Enrolled126ConditionsImmune Thrombocytopenia With Positive ANA AntibodiesArmsHydroxychloroquine Oral Tablet, Eltrombopag
NCT06479304 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Efficacy and Safety of Hydroxychloroquine Plus Prednisone in Antinuclear Antibody-positive Patients With Primary Immune Thrombocytopenia-- The Multicenter, Randomized, Open-lable Clinical Trial

TypeinterventionalSponsorYunfeng ChengRan2024 to 2026Enrolled129ConditionsImmune Thrombocytopenia With Positive ANA AntibodiesArmsHydroxychloroquine Oral Tablet, Prednisone tablet
NCT06479317 narecruitingnot on this mapstarted 2024, after this paper: background citation

The Efficacy and Safety of Hydroxychloroquine Plus Dexamethasone in Antinuclear Antibody-positive Patients With Primary Immune Thrombocytopenia-- The Multicenter, Randomized, Open-labled Clinical Trial

TypeinterventionalSponsorYunfeng ChengRan2024 to 2026Enrolled129ConditionsImmune Thrombocytopenia With Positive ANA AntibodiesArmsHydroxychloroquine Oral Tablet, Dexamethasone oral
3 · Its place in the literature

Who cites it

180 citing papers in PubMed, 10 syntheses or guidelines pooled it, 444 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

120 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Michele P LambertDivision of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA; and.
Terry B GernsheimerDivision of Hematology, University of Washington School of Medicine, Seattle, WA.
Children's Hospital of Philadelphia · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune thrombocytopenia (ITP) occurs in 2 to 4/100 000 adults and results in variable bleeding symptoms and thrombocytopenia. In the last decade, changes in our understanding of the pathophysiology of the disorder have led to the publication of new guidelines for the diagnosis and management of ITP and standards for terminology. Current evidence supports alternatives to splenectomy for second-line management of patients with persistently low platelet counts and bleeding. Long-term follow-up data suggest both efficacy and safety, in particular, for the thrombopoietin receptor agonists and the occurrence of late remissions. Follow-up of patients who have undergone splenectomy for ITP reveals significant potential risks that should be discussed with patients and may influence clinician and patient choice of second-line therapy. Novel therapeutics are in development to address ongoing treatment gaps.

Indexed as

Purpura, Thrombocytopenic, IdiopathicAdultFemaleHemorrhageHumansMalePlatelet CountPractice Guidelines as TopicReceptors, ThrombopoietinSplenectomyMPL protein, humanReceptors, Thrombopoietin

Identifiers

PMID28416506
PMCPMC5813736
OpenAlexW2606110133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.